Company profile
Arbutus Biopharma
Pipeline2 assets
- ImdusiranAB-729; IDR / HBV viral antigens/HBV RNA transcripts / GalNAc-conjugated RNAi therapeutic; subcutaneous / Infectious disease; hepatitis BChronic hepatitis B (cHBV); IM-PROVE I: imdusiran + peg-IFNα-2a + NAPhase 2aclinicalChronic hepatitis B (cHBV); IM-PROVE II: imdusiran + nivolumab + NA + VTP-300Phase 2aclinical
- AB-101AB-101 / PD-L1 / Oral PD-L1 inhibitor / Infectious disease; hepatitis BChronic hepatitis B (cHBV); AB-101-001 in healthy subjects and cHBV patientsPhase 1a/1bclinical; Part 3 dosing in cHBV patients
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.